* Leap Therapeutics Inc reported a quarterly adjusted loss of 44 cents​​ per share for the quarter , higher than the same quarter last year, when the company reported EPS of -51 cents. The mean expectation of four analysts for the quarter was for a loss of 48 cents per share. Wall Street expected results to range from -53 cents to -37 cents per share.

* Reported revenue was zero​; analysts expected zero.

* Leap Therapeutics Inc's reported EPS for the quarter was a loss of 44 cents​.

* The company reported a quarterly loss of $18.18 million.

* Leap Therapeutics Inc shares had risen by 26.5% this quarter and lost 21.6% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts was unchanged in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Leap Therapeutics Inc is 12.00 This summary was machine generated from LSEG data November 13 at 02:16 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.48 -0.44 Beat

Jun. 30 2024 -0.43 -0.52 Missed

Mar. 31 2024 -0.58 -0.51 Beat

Dec. 31 2023 -0.55 -0.46 Beat